MedTrace Logo

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

NCT07388615 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-05

No results posted yet for this study

Summary

This study aims to:

1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children.
2. To measure the changes in parasite count in stool samples after treatment with Immulant ®.
3. To assess the safety and tolerability of Immulant ® in children participating in the study.

Conditions

  • Cryptosporidium Infection

Interventions

DRUG

Echinacea Extract

Immulant ® (an extract derived from Echinacea purpurea plant)

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-18
Primary Completion
2026-06-30
Completion
2026-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07388615 on ClinicalTrials.gov